The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback